Matinas BioPharma Holdings (MTNB) Payables (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Payables of $712000.0 for Q1 2026, up 152.48% year-over-year from $282000.0 in Q1 2025, and up 126.03% quarter-over-quarter from $315000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Payables (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Payables data on file, last reported at $712000.0 in Q1 2026.
- Payables for Q1 2026 came in at $712000.0, up 152.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $712000.0 (up 152.48% YoY), and the FY2025 annual result was $315000.0, up 231.58% from the prior year.
- Payables grew to $712000.0 in Q1 2026 per MTNB's latest filing, from $315000.0 in the prior quarter.
- Over five years, Payables peaked at $1.8 million in Q3 2023 and troughed at $80000.0 in Q3 2025.
- A 5-year average of $587869.0 and a median of $497151.0 in 2022 frame the typical range for Payables.
- The sharpest annual moves came in 2024 and 2025: Payables sank 82.65% in 2024, then soared 231.58% in 2025.
- A 5-year view of Payables shows it stood at $618000.0 in 2022, then declined by 16.83% to $514000.0 in 2023, then tumbled by 81.52% to $95000.0 in 2024, then soared by 231.58% to $315000.0 in 2025, then soared by 126.03% to $712000.0 in 2026.
- Business Quant data shows MTNB's Payables at $712000.0 in Q1 2026, $315000.0 in Q4 2025, and $80000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 300,549.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 8.69 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 34.55 Mn |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | 712,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 712,000.00 |
| Dec 31, 2025 | 315,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 167,000.00 |
| Mar 31, 2025 | 282,000.00 |
| Dec 31, 2024 | 95,000.00 |
| Sep 30, 2024 | 349,000.00 |
| Jun 30, 2024 | 238,000.00 |
| Mar 31, 2024 | 473,000.00 |
| Dec 31, 2023 | 514,000.00 |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | 516,000.00 |
| Dec 31, 2022 | 618,000.00 |
| Sep 30, 2022 | 656,717.00 |
| Jun 30, 2022 | 497,151.00 |
| Mar 31, 2022 | 1.35 Mn |
| Dec 31, 2021 | 937,000.00 |
| Sep 30, 2021 | 661,998.00 |
| Jun 30, 2021 | 450,461.00 |